Human Leukocyte Antigen and Antigen Processing Machinery Component Defects in Astrocytic Tumors

Abstract

The presence of HLA antigen defects in malignant brain tumors may provide an explanation for the relatively poor clinical response rates observed in the majority of the T cell-based immunotherapy clinical trials conducted to date in patients with malignant brain tumors.